Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 3/20 | 0.63 |
| ▸ | FDPS | P14324 | 4/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309888 | 0.84 | LAP3 (0.87) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL1058893 | 0.84 | LAP3 (0.87) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL7814294 | 0.77 | LAP3 (1.00) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL625939 | 0.77 | LAP3 (1.00) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL1060233 | 0.76 | LAP3 (1.00) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL1059770 | 0.76 | LAP3 (1.00) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL9307335 | 0.76 | LAP3 (1.00) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL5691911 | 0.76 | LAP3 (1.00) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL5691588 | 0.76 | LAP3 (1.00) | LAP3FDPSS1PR2S1PR1S1PR3 | |
| SCHEMBL745344 | 0.76 | LAP3 (1.00) | LAP3FDPSS1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010259-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010259-A1 | Methods of Treating an Overweight or Obese Subject | METAP2, METAP1, ACER2 | LAP3 615/4885FDPS 506/4885S1PR2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.